150 related articles for article (PubMed ID: 37294084)
1. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
[TBL] [Abstract][Full Text] [Related]
2. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
3. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
[TBL] [Abstract][Full Text] [Related]
4. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
6. Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia.
McCormick M; Lapinski J; Friehling E; Smith K
Pediatr Blood Cancer; 2021 Aug; 68(8):e29051. PubMed ID: 33860989
[TBL] [Abstract][Full Text] [Related]
7. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
8. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
9. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
[TBL] [Abstract][Full Text] [Related]
10. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
[TBL] [Abstract][Full Text] [Related]
11. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Cooper SL; Young DJ; Bowen CJ; Arwood NM; Poggi SG; Brown PA
Pediatr Blood Cancer; 2019 Aug; 66(8):e27797. PubMed ID: 31099154
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
13. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
14. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
15. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hypersensitivity reactions to cancer chemotherapeutic agents in pediatric patients.
Turgay Yagmur I; Guzelkucuk Z; Yarali N; Ozyoruk D; Toyran M; Civelek E; Ozbek NY; Dibek Misirlioglu E
Ann Allergy Asthma Immunol; 2020 Apr; 124(4):350-356. PubMed ID: 31981613
[TBL] [Abstract][Full Text] [Related]
17. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
19. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]